Liver cancer recurrence study
Part of Cancer, Digestive system clinical trials.
This study tracks patients with liver cancer who have had surgery to see how often the cancer comes back. It may help doctors better understand and predict recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer, confirmed by a biopsy.
- You had surgery for your first liver cancer, or for a recurrence or persistent disease after treatment.
- Your enrollment assessment was done on or after February 2, 2019.
- You have not had surgery to shrink the tumor before a liver transplant.
- You have not had surgery that wasn't meant to cure (like palliative care).
- You have not had a mixed type liver cancer (like hepatocholangiocarcinoma) or any other cancer in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a database of people with liver cancer (including hepatocellular carcinoma and other types). It aims to collect health information and samples over time to better understand the disease and improve future care. If you join, you will be asked to provide blood and leftover tissue from surgery or biopsy, and to follow up with the research team.
This trial uses a simple blood test to check for signs of liver cancer coming back after surgery. It may help doctors catch a return earlier and guide further treatment.
This study compares surgery versus watch-and-wait for people whose liver cancer shrank significantly after treatment. It aims to find out if surgery is always needed or if watching closely is just as good.
This study checks whether a simple blood test (called ctDNA) can predict if liver cancer will come back after surgery. It compares the blood test to a standard lab result from the removed tumor, which may help doctors plan better follow-up care.
This trial studies patients with liver cancer, including both the common type (hepatocellular carcinoma) and other types. It aims to understand the cancer better by collecting blood samples and medical information.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.